A Multicentre, Randomized, Double-blind, Parallel Group, Placebocontrolled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Plus Long-acting ?2 Agonist in Patients with Uncontrolled Asthma (SIRO

Project: Other project

StatusFinished
Effective start/end date6/18/146/17/16

Funding

  • AstraZeneca LP: $5,673.08